CAR19-41BB-CD3z-mIL15-T cells

CAR19-41BB-CD3z-mIL15-T cells are autologous or allogeneic T cells genetically engineered to express a chimeric antigen receptor (CAR) targeting CD19, with a second-generation intracellular signaling domain combining 4-1BB (CD137) and CD3 zeta (CD3ζ), and co-expressing membrane-bound interleukin-15 (IL-15). These CAR-T cells are designed for enhanced treatment of B-cell malignancies, notably relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The inclusion of the 4-1BB costimulatory domain improves persistence and activation of the CAR-T cells, while membrane-bound IL-15 promotes T-cell proliferation, survival, and resistance to exhaustion, leading to enhanced expansion, engraftment, and anti-tumor activity. The engineered T cells recognize and bind to CD19 on the surface of malignant B cells, resulting in direct cytotoxic effector function primarily through the release of cytolytic molecules (such as perforin and granzyme) and secretion of proinflammatory cytokines. Expression of membrane-bound IL-15 further remodels the tumor microenvironment, enhances NK cell activation, and reduces immunosuppressive macrophages[1][3][5].

Other names

CD19 CAR-T cells with membrane-bound IL-15CD-19 CAR-T cells with membrane-bound IL-15CD 19 CAR-T cells with membrane-bound IL-15CAR19-41BB-CD3ζ-mIL15-T cells